Why Inhalation

Taking the direct route to treat
cardiovascular conditions.

Pulmonary Delivery and Cardiovascular Conditions

Inhaled delivery of antiarrhythmic drugs potentially present a unique opportunity in the ability to deliver the drug straight to the heart via the lungs as a fast acting patient-administered medicine that then could quickly resolve disabling symptoms associated with Paroxysmal Atrial Fibrillation (>11.5 million global prevalence).

InCarda’s lead product candidate is InRhythm™, an inhaled version of a first line antiarrhythmic drug. InRhythm is designed to improve the pharmacokinetic (PK) profile of the antiarrhythmic, with the aim of enhancing efficacy without compromising the known safety and tolerability profile. Initial studies have shown rapid conversion of AF to normal sinus rhythm.

WhyInhalation-venndiagram

The Promise of Inhalation

1. Patient-administered at home, work or on the go
2. Potential for a faster treatment at onset of symptoms
3. Potential to reduce heart-damaging effects of a delayed treatment
4. May reduce the need to visit the ER, ultimately lowering healthcare costs
5. Potential to improve overall quality of life
6. Efficacy of an IV with the convenience of a pill
7. May slow progression of disease

Pulmonary Delivery Application for Cardiovascular Conditions

InCarda’s technologies hold significant promise in effectively treating heart conditions such as:

AtrialFibrillation-ECG

Paroxysmal Atrial Fibrillation (PAF)

Patients are usually diagnosed with PAF as defined by episodes of AF that spontaneously revert to normal rhythm within seven days of onset. Patients with paroxysmal AF often experience multiple symptomatic episodes per year. Because of the progressive nature of AF, paroxysmal AF may progress to persistent or permanent AF, and persistent AF may progress to permanent AF.
Quick Facts:
  • AF accounts for > $26B annually in U.S. healthcare costs1, 70% of which are hospital-related costs
  • Approximately 2.9M patients worldwide have weekly PAF episodes
  • PAF progresses to persistent or permanent AF at a rate of 13% annually
  • PAF patients frequent the Emergency Room to seek treatment and sometimes require extended hospital stays
  • Around 93% of diagnosed prevalent cases of AF have a significantly elevated risk of stroke
  • Current treatment methods are slow and/or inadequate
More about our PAF Product

1Kim H Michael, Circulation Cardiovasc Qual Outcomes, May 2011

For more information about InCarda: